CClinicalTrials.gg
CompletedNCT03884946Updated Jan 29, 2026Results posted

The Getting Off App for Methamphetamine-Using Gay and Bisexual Men

An interventional study of Getting Off App in Methamphetamine Abuse and HIV/AIDS, sponsored by Friends Research Institute, Inc.. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Friends Research Institute, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

A commonly used manualized outpatient methamphetamine intervention for gay and bisexual men, "Getting Off," is being translated into a mobile phone application (i.e., app) available for download through common app marketplaces. The application will provide games, guided lessons, informational support, and resources to gay and bisexual men seeking to reduce their methamphetamine use and risky sexual behaviors.

Read the detailed description

The research team will conduct formative research to translate the 24 Getting Off sessions from a group-based manual-driven intervention to a computerized app, conduct alpha phase post-development bug testing, conduct beta phase usability pilot testing, and refine the app according to alpha- and beta-phase testing. Four focus groups will provide input on the development of the Getting Off app (further input will be obtained through an ongoing Consumer Advisory Board and usability pilot testing) with: 1) out-of-treatment, methamphetamine-using MSM (n=\~8); 2) methamphetamine-using men who have sex with men (MSM) who are currently in outpatient treatment in the brick-and-mortar Getting Off program at the study site (n=\~8); 3) prior methamphetamine-using MSM with a minimum of one year recovery who have completed a minimum 18/24 sessions (75%) of the brick-and-mortar Getting Off program; and, 4) prior methamphetamine-using MSM with a minimum of one year recovery who have had no previous experience or knowledge of the Getting Off intervention (n=\~8). The focus groups will be structured to provide guidance on translating Getting Off into an app that is responsive to culture (e.g., sexuality; HIV prevention/care including pre-exposure prophylaxis (PrEP) uptake, adherence and persistence, antiretroviral therapy (ART) adherence, viral load suppression) and methamphetamine treatment needs.

Following app development, and to ensure benchmarks have been met, alpha phase testing will uncover and remove unwanted bugs, and beta phase usability pilot testing will be conducted with members of the target population (N=30) to test the feasibility, acceptability, and preliminary effects of the Getting Off app. Furthermore, the pilot testing will be utilized to ensure the functionality of the app (i.e., that the app is user-friendly and all features function appropriately).

Behavioral assessments will be conducted at baseline and at 1-month follow-up.

The study team will then conduct a randomized controlled trial (RCT) to evaluate reductions of methamphetamine use and HIV sexual risk behaviors, and increased advancement along the HIV Prevention or Care Continuum, using three approaches: a) two-arm RCT to determine intervention effects through comparison of the immediate delivery (ID; n=150) and delayed delivery (DD; n=150) arms; b) an observed treatment effects analysis powered for prospective sub-group to compare longitudinal pre/post data from the pooled ID and DD arms (N=300); and, c) a two-arm historical matched comparison design to evaluate the outcomes of the Getting Off app (ID+DD; N=300) relative to a matched sample of participants having previously attended the brick-and-mortar group-based Getting Off intervention (N\~600; total N=900).

Following screening, informed consent and baseline assessments, participants will be randomized into one of two arms: Arm A: Immediate access to the Getting Off app (ID); or, Arm B: Participants will have access to the Getting Off app after a delayed 30-day period (DD). Participants in both arms will receive the same Getting Off app and participants in both arms will be given 30-days to engage with the app. The randomized two-arm repeated measures design will assess participants at 1-, 2- (DD arm only), 3-, 6-, and 9-months post-randomization to determine longitudinal intervention effects, observed treatment effects, and a historical comparison with a matched sample of participants who have attended the brick-and-mortar group-based Getting Off intervention.

02

Conditions studied

  • Methamphetamine Abuse
  • HIV/AIDS

Keywords

  • MSM
  • mHealth
  • App
03

In context

Acquired Immunodeficiency Syndrome

2,040 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 272 are open to participants now.

This study's enrollment of 226 is above the median of 105 across 1,543 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Friends Research Institute, Inc. is the lead sponsor of 44 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

Self-identified man who has sex with men (MSM) Any methamphetamine use in the past 365 days Between the ages of 18-65 years Able and willing to provide informed consent.

Exclusion criteria

Exclusion Criteria:

Did not identify as a man who had sex with a man No methamphetamine use in the past 365 days Younger than 18 or older than 65 years Not able or willing to provide informed consent.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
226 participants (actual)

Study arms

  • Active comparator
    Immediate Delivery

    Participants randomized into the Immediate Delivery arm (n = 113) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.

    Other: Getting Off App

  • Placebo comparator
    Delayed Delivery

    Participants randomized into the Delayed Delivery arm (n = 113) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).

    Other: Getting Off App

Interventions

  • OtherGetting Off App

    A mobile phone application based on the "Getting Off" methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included.

06

What researchers measure

Primary outcomes

  1. Methamphetamine Use

    Days of participant self-reported methamphetamine use in the past 30 days.

    Time frame: from baseline to 9-months post randomization

  2. Methamphetamine Injection

    Days participants self-reported methamphetamine injection use in past 30 days

    Time frame: From baseline to 9-months post randomization

  3. Condomless Anal Intercourse

    Reporting condomless anal intercourse in the past 30 days (yes/no)

    Time frame: baseline to 9-months post randomization

  4. Condomless Anal Intercourse While High on Methamphetamine

    Reporting condomless anal intercourse while high on methamphetamine in the past 30 days (yes/no)

    Time frame: 9-months post randomization

Secondary outcomes

  1. ART Initiation

    Starting to receive ART among HIV sero-positive participants who were not on ART at baseline (yes/no)

    Time frame: 9-months post randomization

  2. PrEP Initiation

    Starting to receive PrEP among HIV sero-negative participants who were not on PrEP at baseline (Yes/No)

    Time frame: 9-months post randomization

07

Results

Posted Jan 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneImmediate Delivery (ID; n=113)Delayed Delivery (DD; n=113)
Started113113
Completed8594
Not completed2819

Outcome measures

PrimaryMethamphetamine Use

Days of participant self-reported methamphetamine use in the past 30 days.

Time frame:
from baseline to 9-months post randomization
Reported as:
Mean · days
Methamphetamine Use
daysImmediate Delivery (ID)Delayed Delivery (DD)
Baseline13.6 ± 11.315.3 ± 11.2
1 month10.9 ± 10.314.5 ± 11.8
2 months—14.4 ± 10.7
3 months9.4 ± 10.013.4 ± 11.6
6 months10.2 ± 10.713.2 ± 11.6
9 months8.8 ± 9.611.7 ± 11.5
PrimaryMethamphetamine Injection

Days participants self-reported methamphetamine injection use in past 30 days

Time frame:
From baseline to 9-months post randomization
Reported as:
Mean · days
Methamphetamine Injection
daysImmediate Delivery (ID)Delayed Delivery (DD)
Baseline2.2 ± 5.52.3 ± 5.9
1 month1.2 ± 4.42.3 ± 5.8
2 months—2.4 ± 6.1
3 months0.7 ± 2.81.6 ± 4.6
6 months1.3 ± 4.71.6 ± 5.4
9 months0.8 ± 2.90.8 ± 3.4
PrimaryCondomless Anal Intercourse

Reporting condomless anal intercourse in the past 30 days (yes/no)

Time frame:
baseline to 9-months post randomization
Reported as:
Count of participants · Participants
Condomless Anal Intercourse
ParticipantsImmediate Delivery (ID)Delayed Delivery (DD)
Baseline6354
1 month4055
2 months—36
3 months3236
6 months3835
9 months4032
PrimaryCondomless Anal Intercourse While High on Methamphetamine

Reporting condomless anal intercourse while high on methamphetamine in the past 30 days (yes/no)

Time frame:
9-months post randomization
Reported as:
Count of participants · Participants
Condomless Anal Intercourse While High on Methamphetamine
ParticipantsImmediate Delivery (ID)Delayed Delivery (DD)
Baseline5649
1 month3042
2 months—30
3 months2632
6 months2628
9 months2623
SecondaryART Initiation

Starting to receive ART among HIV sero-positive participants who were not on ART at baseline (yes/no)

Time frame:
9-months post randomization
Reported as:
Count of participants · Participants
ART Initiation
ParticipantsImmediate Delivery (ID)Delayed Delivery (DD)
ART Initiation25
SecondaryPrEP Initiation

Starting to receive PrEP among HIV sero-negative participants who were not on PrEP at baseline (Yes/No)

Time frame:
9-months post randomization
Reported as:
Count of participants · Participants
PrEP Initiation
ParticipantsImmediate Delivery (ID)Delayed Delivery (DD)
PrEP Initiation47

Adverse events

Collected over Up to 9 months post randomization. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Delivery0/113 (0%)0/113 (0%)0/113 (0%)
Delayed Delivery0/113 (0%)0/113 (0%)0/113 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Immediate DeliveryDelayed DeliveryTotal
Mean45.3 ± 9.545.3 ± 10.345.3 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Immediate DeliveryDelayed DeliveryTotal
Female000
Male113113226
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Immediate DeliveryDelayed DeliveryTotal
Hispanic or Latino403777
Not Hispanic or Latino6367130
Unknown or Not Reported10919
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Immediate DeliveryDelayed DeliveryTotal
American Indian or Alaska Native134
Asian123
Native Hawaiian or Other Pacific Islander101
Black or African American272956
White524496
More than one race111122
Unknown or Not Reported202444
Region of Enrollment
Region of Enrollment(Participants)Immediate DeliveryDelayed DeliveryTotal
United States113113226
Baseline Methamphetamine Use
Baseline Methamphetamine Use(days)Immediate DeliveryDelayed DeliveryTotal
Mean13.6 ± 11.314.5 ± 11.814.4 ± 11.3
08

Study locations

1 site
  • Friends Community Center
    Los Angeles, California 90038, United States
09

References and documents

Publications

  • Reback CJ, Fletcher JB, Mata RP. A Theory-Based mHealth Intervention (Getting Off) for Methamphetamine-Using Men Who Have Sex With Men: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2021 Feb 22;10(2):e22572. doi: 10.2196/22572. PubMed 33616547 ↗

Study documents

  • Protocol and statistical analysis plan · Sep 2, 2021
  • Informed consent form · Nov 2, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — No current plan to share IPD.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03884946
Lead sponsor
Friends Research Institute, Inc.
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Sponsor
First posted
Mar 21, 2019
Start date
Jan 30, 2019
Primary completion
Apr 26, 2024
Completion
Apr 26, 2024
Results posted
Jan 29, 2026
Last update
Jan 29, 2026

Study contacts

Cathy Reback, Ph.D.
principal investigator · Friends Research Institute, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion